Clincosm LogoSign in Get a demo

CAPItello-291: Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Sponsor
AstraZeneca (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04305496
Collaborator
(none)
834
Enrollment
266
Locations
2
Arms
49.7
Anticipated Duration (Months)
3.1
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
834 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Double-blind Randomised StudyDouble-blind Randomised Study
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor
Actual Study Start Date :
Apr 16, 2020
Anticipated Primary Completion Date :
Aug 15, 2022
Anticipated Study Completion Date :
Jun 7, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Capivasertib + fulvestrant

Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter. Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle.

Drug: Fulvestrant
Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

Drug: Capivasertib
400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Placebo Comparator: Placebo + fulvestrant

Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter. Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle.

Drug: Fulvestrant
Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter

Drug: Placebo
Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle

Outcome Measures

Primary Outcome Measures

  1. Progression-Free Survival (PFS) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup [The time from date of randomisation to the date of progression or death due to any cause, whichever occurs earlier, up to approximately 51 months]

    Progression-Free Survival by investigator assessment (in accordance with RECIST 1.1)

Secondary Outcome Measures

  1. Overall Survival (OS) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup. [The time from date of randomisation to the date of death due to any cause up to 51 months]

    Overall Survival (OS) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup

  2. Investigator assessment of PFS2 in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup. [The time from the date of randomisation to the date of progression subsequent to the first subsequent therapy, or death due to any cause, whichever occurs earlier, up to approximately 51 months]

    PFS2 - time from randomisation to second progression by investigator assessment

  3. Response Rate (ORR) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup. [Up to Approximately 51 months]

    percentage of patients with at least one investigator-assessed visit response of complete or partial response (as assessed by the investigator, using RECIST 1.1)

  4. Duration of Response (DoR) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup. [Up to Approximately 51 months]

    time from the date of first documented response until date of documented progression (as assessed by the investigator, using RECIST 1.1) or death in the absence of disease progression

  5. Clinical Benefit Rate (CBR) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup. [Up to Approximately 51 months]

    number of patients with complete or partial response or with stable disease maintained ≥24 weeks after randomisation (as assessed by the investigator, using RECIST 1.1)

  6. ocurrence/frequency of AEs and its relationship to study drugs (safety and tolerability) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup [Up to Approximately 51 months]

    AEs graded according to the National Cancer Institute (NCI CTCAE)

  7. plasma concentration of capivasertib [Minimum plasma concentration (Cmin), plasma concentration 1 hour post-dose (C1h) and 4 hours post-dose (C4h) during cycles 1 and 2 (each cycle is 28 days)]

    plasma concentration of capivasertib pre-dose and post-dose (C1h and C4h) in the overall population

  8. EORTC QLQ BR23(European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire breast cancer specific module) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup where applicable [Up to Approximately 51 months]

    The self-administered instrument includes 23-items and yields 5 multi-item scores (body image, sexual functioning, arm symptoms, breast symptoms, and systemic therapy side effects). Items are scored on a 4-point verbal rating scale: "Not at All," "A Little," "Quite a Bit," and "Very Much". Scores are transformed to a 0 to 100 scale, where higher scores indicate better unctioning, better HRQoL, or greater level of symptom

  9. The EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup where applicable [Up to Approximately 51 months]

    5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), and global health status/QoL scale, along with 5 individual item symptom scores (appetite loss, dyspnoea, insomnia, constipation, and diarrhoea. The EORTC QLQ-C30 will be scored according to the EORTC QLQ-C30 Scoring Manual (Fayers et al. 2001). Higher scores on the global measure of health status and functional scales indicate better health status/function, but higher scores on symptom scales/scores represent greater symptom severity

  10. Time to definitive deterioration of the ECOG (Eastern Cooperative Oncology Group) performance status in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup where applicable [Up to approximately 51 months]

    Time from randomisation to the earlier of the date of the first definitive deterioration or death due to any cause. Deterioration is defined as a 1-point decrease in ECOG score from baseline, and the deterioration is considered definitive if no improvements in the ECOG performance status are observed at a subsequent time of measurement during the treatment period, or at no further assessments following the time point where the deterioration is observed

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 130 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study

  2. Histologically confirmed HR+/HER2- breast cancer determined from the most recent tumour sample (primary or metastatic), as per the American Society of Clinical Oncology and College of American Pathologists guideline recommendations. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.

  3. Metastatic or locally advanced disease with radiological or objective evidence of recurrence or progression (the cancer should have shown progression during or after most recent therapy); locally advanced disease must not be amenable to resection with curative intent (patients who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible)

  4. ECOG/WHO PS: 0-1

  5. Patients are to have received treatment with an AI (aromatase inhibitor) containing regimen (single agent or in combination) and have:

  6. Radiological evidence of breast cancer recurrence or progression while on, or within 12 months of the end of (neo)adjuvant treatment with an AI, OR

  7. Radiological evidence of progression while on prior AI administered as a treatment line for locally advanced or metastatic breast cancer (this does not need to be the most recent therapy)

  8. Patients must have measurable disease according to RECIST 1.1 and/or at least 1 lytic or mixed (lytic + sclerotic) bone lesion that can be assessed by CT or MRI; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible

  9. FFPE tumour sample from primary/recurrent cancer for central testing

Exclusion Criteria:

  1. Symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgement

  2. More than 2 lines of endocrine therapy for inoperable locally advanced or metastatic disease

  3. More than 1 line of chemotherapy for inoperable locally advanced or metastatic disease. Adjuvant and neoadjuvant chemotherapy are not classed as lines of chemotherapy for advanced breast cancer

  4. Prior treatment with any of the following:

  5. AKT, PI3K and mTOR inhibitors

  6. Fulvestrant, and other SERDs

  7. Any other chemotherapy, immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents within 3 weeks prior to study treatment initiation.

  8. Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort) or drugs that are sensitive to CYP3A4 inhibition within 1 week prior to study treatment initiation.

  9. Radiotherapy with a wide field of radiation up to 4 weeks before study treatment initiation (capivasertib/placebo) and/or radiotherapy with a limited field of radiation for palliation up to 2 weeks before study treatment initiation (capivasertib/placebo)

  10. With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment

  11. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids up to 4 weeks before study treatment initiation

  12. Any of the following cardiac criteria:

  13. Mean resting QT interval corrected by Fridericia's formula (QTcF) >470 msec obtained from 3 consecutive ECGs

  14. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block)

  15. Any factors that increase the risk of corrected QT interval (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval

  16. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) grade ≥2

  17. Uncontrolled hypotension - systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg

  18. Cardiac ejection fraction outside institutional range of normal or <50% (whichever is higher) as measured by echocardiogram (or multiple-gated acquisition [MUGA] scan if an echocardiogram cannot be performed or is inconclusive)

  19. Clinically significant abnormalities of glucose metabolism as defined by any of the following:

  20. Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment

  21. HbA1c ≥8.0% (63.9 mmol/mol)

  22. Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant or LHRH agonist (if applicable)

  23. Currently pregnant (confirmed with positive pregnancy test) or breast-feeding

Contacts and Locations

Locations

Site City State Country Postal Code
1 Research Site Gilbert Arizona United States 85234
2 Research Site Tucson Arizona United States 85715
3 Research Site Tucson Arizona United States 85745
4 Research Site Orange California United States 92868
5 Research Site Redlands California United States 92373-4870
6 Research Site San Francisco California United States 94143
7 Research Site Santa Maria California United States 93454
8 Research Site Thousand Oaks California United States 91361
9 Research Site Whittier California United States 90603
10 Research Site Whittier California United States 90603
11 Research Site Fort Myers Florida United States 33905
12 Research Site Jacksonville Florida United States 32224
13 Research Site Orlando Florida United States 32804
14 Research Site Marietta Georgia United States 30060
15 Research Site Westwood Kansas United States 66205
16 Research Site Baltimore Maryland United States 21201
17 Research Site Boston Massachusetts United States 02111-1520
18 Research Site Royal Oak Michigan United States 48073
19 Research Site Rochester Minnesota United States 55905
20 Research Site Kansas City Missouri United States 64132
21 Research Site Saint Louis Missouri United States 63156
22 Research Site Henderson Nevada United States 89052
23 Research Site Paramus New Jersey United States 07652
24 Research Site Farmington New Mexico United States 87401
25 Research Site Lake Success New York United States 11042
26 Research Site New York New York United States 10011
27 Research Site New York New York United States 10065
28 Research Site Rochester New York United States 14642
29 Research Site Greensboro North Carolina United States 27403
30 Research Site Cleveland Ohio United States 44106
31 Research Site Chattanooga Tennessee United States 37404
32 Research Site Nashville Tennessee United States 37211
33 Research Site Dallas Texas United States 75246
34 Research Site Midlothian Virginia United States 23114
35 Research Site Puyallup Washington United States 98373
36 Research Site Berazategui Argentina B1884BBF
37 Research Site Ciudad Autonoma De Buenos Aire Argentina C1125ABD
38 Research Site La Rioja Argentina 5300
39 Research Site Rosario Argentina S2000KZE
40 Research Site Viedma Argentina R8500ACE
41 Research Site Adelaide Australia 5000
42 Research Site Ballarat Australia 3350
43 Research Site Birtinya Australia 4575
44 Research Site Box Hill Australia 3128
45 Research Site Concord Australia 2139
46 Research Site East Albury Australia 2640
47 Research Site Kurralta Park Australia 5037
48 Research Site North Sydney Australia 2060
49 Research Site Orange Australia 2800
50 Research Site Ringwood East Australia 3135
51 Research Site South Brisbane Australia 4101
52 Research Site Waratah Australia 2298
53 Research Site Wendouree Australia 3355
54 Research Site Brussels Belgium 1090
55 Research Site Bruxelles Belgium 1200
56 Research Site Charleroi Belgium 6000
57 Research Site Edegem Belgium 2650
58 Research Site Namur Belgium 5000
59 Research Site Wilrijk Belgium 2610
60 Research Site Winnipeg Manitoba Canada R3E 0V9
61 Research Site Kingston Ontario Canada K7L 2V7
62 Research Site Mississauga Ontario Canada L5M 2N1
63 Research Site North York Ontario Canada M2K 1E1
64 Research Site Toronto Ontario Canada M3M 0B2
65 Research Site Toronto Ontario Canada M4N 3M5
66 Research Site Toronto Ontario Canada M5G 1X5
67 Research Site Montreal Quebec Canada H2X 3E4
68 Research Site Montreal Quebec Canada H4A 3J1
69 Research Site Saskatoon Saskatchewan Canada S7N 4H4
70 Research Site Baoding China 071000
71 Research Site Beijing China 100034
72 Research Site Beijing China 100044
73 Research Site Beijing China 100191
74 Research Site Beijing China 100210
75 Research Site Beijing China 100730
76 Research Site Changchun China 130021
77 Research Site Chengdu China 610041
78 Research Site Chongqing China 400010
79 Research Site Chongqing China 400030
80 Research Site Dalian China 116011
81 Research Site Foshan China 528000
82 Research Site Gongshu District China 310022
83 Research Site Guangzhou China 510080
84 Research Site Guangzhou China 510095
85 Research Site Guangzhou China 510289
86 Research Site Hangzhou China 310003
87 Research Site Hangzhou China 310020
88 Research Site Harbin China 150081
89 Research Site Hefei China 230001
90 Research Site Hefei China 230022
91 Research Site Jinan China 250001
92 Research Site Jinan China 250117
93 Research Site Linyi China 276000
94 Research Site Nanchang China 330009
95 Research Site Nantong China 226001
96 Research Site Neijiang China 641000
97 Research Site Shanghai China 200032
98 Research Site Shanghai China 200127
99 Research Site Shantou China CN-515031
100 Research Site Shenyang China 110001
101 Research Site Shenyang China 110042
102 Research Site Tianjin China 300060
103 Research Site Wuhan China 430022
104 Research Site Wuhan China 430030
105 Research Site Wuhan China 430079
106 Research Site Xi'an China 710004
107 Research Site Xuzhou China 221006
108 Research Site Zhengzhou City China 450008
109 Research Site Zhengzhou China 450003
110 Research Site Besancon France 25000
111 Research Site Brest France 29609
112 Research Site Metz Cedex 03 France 57085
113 Research Site Pierre Benite CEDEX France 69310
114 Research Site Plerin SUR MER France 22190
115 Research Site Pringy France 74374
116 Research Site Rouen France 76038
117 Research Site STRASBOURG Cedex France 67065
118 Research Site Toulouse cedex 9 France 31059
119 Research Site Berlin Germany 10367
120 Research Site Cottbus Germany 03048
121 Research Site Dresden Germany 01307
122 Research Site Erlangen Germany 91054
123 Research Site Essen Germany 45130
124 Research Site Frankfurt am Main Germany 60431
125 Research Site Frankfurt Germany 60389
126 Research Site Gelsenkirchen Germany 45879
127 Research Site Hamburg Germany 20246
128 Research Site Hamburg Germany 20249
129 Research Site Hamburg Germany 20357
130 Research Site Hannover Germany 30625
131 Research Site Heidelberg Germany 69120
132 Research Site Jena Germany 07747
133 Research Site Kiel Germany 24105
134 Research Site Mannheim Germany 68167
135 Research Site Minden Germany 32429
136 Research Site Muenchen Germany 81377
137 Research Site München Germany 80637
138 Research Site München Germany 81675
139 Research Site Münster Germany 48149
140 Research Site Paderborn Germany 33161
141 Research Site Potsdam Germany 14467
142 Research Site Budapest Hungary 1032
143 Research Site Budapest Hungary 1122
144 Research Site Budapest Hungary 1134
145 Research Site Debrecen Hungary 4032
146 Research Site Kecskemét Hungary 6000
147 Research Site Pécs Hungary 7624
148 Research Site Szekszárd Hungary 7100
149 Research Site Szolnok Hungary 5000
150 Research Site Afula Israel 1834111
151 Research Site Beer Sheva Israel 84101
152 Research Site Haifa Israel 31096
153 Research Site Jerusalem Israel 91031
154 Research Site Jerusalem Israel 91120
155 Research Site Kfar-Saba Israel 4428164
156 Research Site Petah Tikva Israel 49100
157 Research Site Ramat Gan Israel 52621
158 Research Site Bergamo Italy 24127
159 Research Site Candiolo Italy 10060
160 Research Site Catanzaro Italy 88100
161 Research Site Genova Italy 16132
162 Research Site Livorno Italy 57124
163 Research Site Macerata Italy 62100
164 Research Site Meldola Italy 47014
165 Research Site Milano Italy 20141
166 Research Site Modena Italy 41124
167 Research Site Napoli Italy 80131
168 Research Site Prato Italy 59100
169 Research Site Reggio Nell'emilia Italy 42123
170 Research Site Roma Italy 00128
171 Research Site Chiba-shi Japan 260-8717
172 Research Site Chuo-ku Japan 104-0045
173 Research Site Chuo-ku Japan 104-8560
174 Research Site Fukuoka-shi Japan 811-1395
175 Research Site Fukushima-shi Japan 960-1295
176 Research Site Hidaka-shi Japan 350-1298
177 Research Site Hiroshima-shi Japan 730-8518
178 Research Site Kagoshima-shi Japan 892-0833
179 Research Site Kitaadachi-gun Japan 362-0806
180 Research Site Koto-ku Japan 135-8550
181 Research Site Kumamoto-shi Japan 860-8556
182 Research Site Kyoto-shi Japan 606-8507
183 Research Site Matsuyama-shi Japan 791-0280
184 Research Site Nagoya-shi Japan 464-8681
185 Research Site Nagoya-shi Japan 467-0001
186 Research Site Osaka-shi Japan 540-0006
187 Research Site Osaka-shi Japan 541-8567
188 Research Site Ota-shi Japan 373-8550
189 Research Site Sapporo-shi Japan 003-0804
190 Research Site Sapporo-shi Japan 060-8638
191 Research Site Shinagawa-ku Japan 142-8666
192 Research Site Tsu-shi Japan 514-8507
193 Research Site Yokohama-shi Japan 241-8515
194 Research Site Busan Korea, Republic of 49241
195 Research Site Daegu Korea, Republic of 41931
196 Research Site Goyang-si Korea, Republic of 10408
197 Research Site Incheon Korea, Republic of 22332
198 Research Site Seongnam-si Korea, Republic of 13620
199 Research Site Seoul Korea, Republic of 03722
200 Research Site Seoul Korea, Republic of 05505
201 Research Site Seoul Korea, Republic of 135-710
202 Research Site Seoul Korea, Republic of 8308
203 Research Site Suwon-si Korea, Republic of 16247
204 Research Site Suwon-si Korea, Republic of 16499
205 Research Site Arequipa Peru AREQUIPA01
206 Research Site Lima Peru LIMA 41
207 Research Site Bydgoszcz Poland 85-796
208 Research Site Krakow Poland 31-501
209 Research Site Olsztyn Poland 10-228
210 Research Site Warszawa Poland 02-781
211 Research Site Kazan Russian Federation 420029
212 Research Site Moscow Russian Federation 111123
213 Research Site Moscow Russian Federation 115478
214 Research Site Saint Petersburg Russian Federation 197758
215 Research Site Saint-Petersburg Russian Federation 198255
216 Research Site Samara Russian Federation 443031
217 Research Site Sochi Russian Federation 354000
218 Research Site A Coruña Spain 15009
219 Research Site Barcelona Spain 08035
220 Research Site Barcelona Spain 8003
221 Research Site Barcelona Spain 8023
222 Research Site Córdoba Spain 14004
223 Research Site Hosp de Llobregat(Barcelona) Spain 08907
224 Research Site Jaén Spain 23007
225 Research Site La Laguna (Tenerife) Spain 38320
226 Research Site Lérida Spain 25198
227 Research Site Madrid Spain 28007
228 Research Site Madrid Spain 28033
229 Research Site Madrid Spain 28034
230 Research Site Madrid Spain 28040
231 Research Site Madrid Spain 28041
232 Research Site Madrid Spain 28046
233 Research Site Majadahonda Spain 28222
234 Research Site Malaga Spain 29010
235 Research Site Pamplona Spain 31008
236 Research Site Reus,Tarragona Spain 43204
237 Research Site Santiago de Compostela Spain 15706
238 Research Site Sevilla Spain 41013
239 Research Site Valencia Spain 46009
240 Research Site Valencia Spain 46010
241 Research Site Kaohsiung City Taiwan 82445
242 Research Site Taichung Taiwan 40447
243 Research Site Tainan City Taiwan 70403
244 Research Site Tainan City Taiwan 710
245 Research Site Tainan Taiwan 710
246 Research Site Taipei Taiwan 10002
247 Research Site Taipei Taiwan 11217
248 Research Site Taipei Taiwan 11259
249 Research Site Taoyuan Taiwan 333
250 Research Site Aberdeen United Kingdom AB25 2ZN
251 Research Site Blackpool United Kingdom FY3 8NR
252 Research Site Bournemouth United Kingdom BH7 7DW
253 Research Site Bristol United Kingdom BS2 8ED
254 Research Site Cardiff United Kingdom CF14 2TL
255 Research Site Cheltenham United Kingdom GL53 7AN
256 Research Site Derby United Kingdom DE22 3NE
257 Research Site Huddersfield United Kingdom HD3 3EA
258 Research Site Lancaster United Kingdom LA1 4RP
259 Research Site Leeds United Kingdom BD7 1DP
260 Research Site London United Kingdom N18 1QX
261 Research Site London United Kingdom NW3 2QG
262 Research Site London United Kingdom SE18 4QH
263 Research Site London United Kingdom SW3 6JJ
264 Research Site Manchester United Kingdom M20 4GJ
265 Research Site Sutton United Kingdom SM25PT
266 Research Site York United Kingdom YO31 8HE

Sponsors and Collaborators

  • AstraZeneca

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT04305496
Other Study ID Numbers:
  • D3615C00001
First Posted:
Mar 12, 2020
Last Update Posted:
Jul 28, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by AstraZeneca
Locally advanced (inoperable) or Metastatic Breast Cancer
Additional relevant MeSH terms:
Breast Neoplasms
Fulvestrant

Study Results

No Results Posted as of Jul 28, 2022